Among the consequences of Alzheimer disease are disturbances in synaptic integrity that ultimately lead to impaired cognitive functions. Thrombospondins are extracellular matrix proteins that, in the CNS, are predominantly produced by astrocytes and have been implicated in synaptogenesis. This study examined the effects of amyloid-A (AA 1-42 ; AA) peptide on intracellular and extracellular levels of thrombospondin 1 (TSP-1) in cultured astrocytes. Amyloid-A caused a significant (1-to 3-fold) increase in astrocytic intracellular levels of TSP-1 (increased retention) that was associated with a reduction of its release from astrocytes. Because AA is known to induce oxidative stress in astrocytes, we examined the effects of the antioxidants tempol and apocynin on astrocytic TSP-1 levels and release. Treatment of AA-exposed astrocyte cultures with antioxidants significantly diminished its cellular retention and stimulated its release. Furthermore, the addition of conditioned media derived from AA-treated cultured astrocytes that contained a reduced TSP-1 content resulted in a significant loss of synaptophysin and PSD95 in cultured neurons. These findings suggest that AA-mediated reduction in astrocytic TSP-1 release, possibly related to oxidative stress, contributes to the loss of synaptophysin in neurons. Strategies aimed at enhancing the astrocytic release of TSP-1 may have a therapeutic benefit in Alzheimer disease.
INTRODUCTION
Alzheimer disease (AD) is the most common neurodegenerative disease. It is associated with severe dementia that affects more than 30 million people worldwide (1) . The histopathologic hallmark of AD is the deposition of amyloid-A (AA ; AA) peptides, leading to the formation of neuritic (senile) plaques. Among several AA peptides, AA is more susceptible to aggregation and is thus considered more neurotoxic (2) . As the disease progresses, extensive deposition of AA aggregates occurs, resulting in neuronal dysfunction and loss, and ultimately leading to severe cognitive impairment (3) . Accordingly, loss of synapses (as evidenced by reduced expression of synaptophysin) in patients with AD, as well as in transgenic mouse models of AD, has been reported (4Y7).
Although most studies in AD have concentrated on neuronal abnormalities, recent attention has focused on the potential role of astrocytes in the pathogenesis of AD (8) . Studies using cultured astrocytes treated with AA have shown metabolic alterations, including increased intracellular release of Ca 2+ (9) , induction of oxidative and nitrosative stress (10) , reduction in glutamate uptake capacity (11Y13), decreased glucose metabolism (14) , and induction of the mitochondrial permeability transition (15) , the latter resulting in mitochondrial dysfunction and bioenergetic failure (8, 16) . Ultimately, all of these astrocytic defects may negatively impact neuronal function.
Recent evidence suggests that astrocytes regulate synapse formation and integrity, which largely occurs through the secretion of the extracellular matrix proteins thrombospondins (TSPs), particularly TSP-1 (17, 18) . Because astrocytic TSPs have been shown to play a critical role in the regulation of neuronal synaptogenesis, we examined the effects of AA on intracellular astrocytic levels and release of TSP-1. We also investigated the effects of conditioned media (CM) from AAtreated astrocytes on the expression of synaptophysin and PSD95, presynaptic and postsynaptic proteins, respectively. Amyloid-A caused a significant reduction in the release of TSP-1 from astrocytes, along with its concomitant intracellular retention. We identified that oxidative stress (OS) significantly contributes to this process. In addition, CM derived from AA-treated astrocytes (containing a reduced TSP-1 content) caused a significant loss of synaptophysin and PSD95 in cultured neurons.
MATERIALS AND METHODS

Reagents
Amyloid-A 1-42 , a synthetic peptide corresponding to human AA, was purchased from American Peptide Company (Sunnyvale, CA). Amicon Ultra centrifugal filter units (with(Cambridge, MA). Rabbit anti-PSD95 antibody was obtained from Cell Signaling Technology (Danvers, MA). Mouse antiYTSP-1 (BA24) and mouse antiY>-tubulin (CP06) antibodies were purchased from Calbiochem-Millipore Inc. (Temecula, CA); human recombinant TSP-1 and human TSP-1 purified from platelets were purchased from Calbiochem (San Diego, CA); protease inhibitor cocktail tablets (Complete Mini) were obtained from Roche Diagnostics (Indianapolis, IN). All other chemicals and reagents were purchased from Sigma Chemical Company (St. Louis, MO) and were of analytical grade.
Astrocyte Cultures
Primary cultures of astrocytes were prepared from cerebral cortices of 1-to 2-day-old rats as described earlier (19) . Briefly, cortices were freed of meninges, minced and dissociated by trituration, passed through sterile nylon sieves, and then placed in Dulbecco modified Eagle medium (Life Technologies, Grand Island, NY) containing penicillin, streptomycin, and 15% fetal bovine serum. Approximately 0.5 Â 10 6 cells were seeded in 35-mm culture plates and maintained at 37-C in an incubator equilibrated with 5% CO 2 and 95% air. Cultures consisted of 97% to 99% astrocytes based on immunofluorescence staining of glial fibrillary acidic protein. After 14 days, the cultures were treated and maintained with dibutyryl cAMP to enhance cell differentiation (20) . Three to 4-week-old cells were used in these experiments.
Neuronal Cultures
Cortical neuronal cultures were prepared by a modification of the method of Hertz and Matz. (21) . Briefly, cerebral cortices were removed from 18-day-old rat fetuses and placed in high-glucose Dulbecco modified Eagle medium containing 25 mmol/L KCl and 20% horse serum. The tissue was minced and mechanically dissociated with a pipette. The dissociated cells were then transferred to Neurobasal medium (catalog no. 21103-049; Life Technologies) supplemented with Glutamax-1 (catalog no. 35050-061; Life Technologies) and sodium pyruvate (1.5 mmol/L). Approximately 1 to 2 Â 10 6 cells/mL were seeded onto poly-l-lysine (pH 9.4)Ycoated 35-mm culture dishes. To prevent proliferation of astrocytes, cytosine arabinoside (10 Kmol/L) was added for 24 hours to the culture medium 48 hours after seeding. These cultures consisted of at least 99% neurons, as determined by immunofluorescence staining for neurofilament protein. Experiments were performed on cultures that were 7 to 9 days old.
Determination of TSP-1 Levels in the Culture Media From AA YTreated Astrocytes
We initially performed dose-response studies on the effects of AA on TSP-1 levels in cultured astrocytes. Thus, treatment of cultures with 2 Kmol/L AA had no effect on cellular levels of TSP-1 nor its release, whereas treatment of astrocytes with a higher concentration (8 Kmol/L) caused cytotoxicity, as shown by the sloughing of cells from the culture plates and by increased release of lactic dehydrogenase (35%, p G 0.05). Accordingly, astrocyte cultures were treated with AA 1-42 (4 Kmol/L) for 1 to 24 hours. For TSP-1 determination, culture media (2 mL) from control and AAtreated astrocytes were collected and transferred to Amicon centrifugal filter tubes (containing cellulose membranes with a 10-kd molecular weight cutoff) and centrifuged at 3,750 Â g for 25 minutes. The solute (200 KL) retained in the filter unit was collected and transferred to Eppendorf tubes. After normalization of protein, TSP-1 levels in the media were determined by immunoblots.
Immunoblotting
Total cell lysates were prepared by harvesting cultures into lysis buffer as previously described (22) . In brief, 200 KL of lysis buffer containing 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L sodium orthovanadate, 1 mmol/L sodium fluoride, 10% glycerol, and 1% Non-iodet P40 (NP-40) containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) was added to each culture plate. Cell extracts were kept on ice for 30 minutes, triturated 5 times, and centrifuged at 10,000 Â g for 20 minutes. The pellet was discarded, and the supernatant was saved for immunoblotting.
Western blot analysis was done in samples after normalization of protein content. Approximately 5 to 10 Kg of sample was separated by 4% to 20% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transblotted onto polyvinylidene difluoride membranes. Immunoblotting was performed using an antibody to TSP-1 (1:2000) , and the detection was carried out using the ECL system (Amersham Biosciences, Piscataway, NJ). Levels of immunoreactive proteins were quantitated by the SigmaScan Pro software after normalizing to >-tubulin levels.
Quantitative Real-time Polymerase Chain Reaction RNA isolation and quantitative polymerase chain reaction (PCR) were performed as previously described using the RNAqueous-4PCR kit (Ambion no. AM1914) (22) . Reverse transcription of RNA to cDNA was performed using 2 Kg of total RNA using the High-Capacity cDNA Reverse Transcription Kit (no. 4368814, Applied Biosystems, Foster City, CA). Quantitative real-time PCR (qPCR) was carried out using 10 KL of 1:20 diluted cDNA on the Mx3005P Multiplex Quantitative PCR System (Stratagen no. 401513) using qPCR SYBR GREEN Reagents (Brilliant II SYBR Green QPCR Master Mix, Agilent Technologies, Santa Clara, CA) with ROX reference dye as a loading control. Rat-specific primer pair sequences for TSP-1 were constructed using NCBI Primer-BLAST. Primer pairs were obtained from Operon Biotechnologies (Huntsville, AL): for elongation factor RPL13a, the forward sequence was 5 ¶-GGCTGAAGCCTAC CAGAAAG-3 ¶, TSP-1 forward sequence was 5 ¶-GGAGG TGCCCGCAAGGTTCC-3 ¶, and the reverse sequence was 5 ¶-TTGTCGGCCCACACAGCGTC-3 ¶. Cycling conditions were as follows: an initial 95-C for 10 minutes, followed by 40 cycles of 95-C for 30 seconds; 58-C for 30 seconds; and 72-C for 15 seconds. All of the corresponding qPCR data were analyzed using the $$CP method (23) and normalized against 1 negative control and the housekeeping gene elongation factor RPL13a.
Treatment of Cultured Neurons With CM From AA-Treated Astrocytes
Astrocyte cultures were initially treated with AA for different periods (6Y24 hours). To remove any residual AA present in media, CM (2 mL each from control and AA-treated astrocytes) were collected and transferred separately into Amicon centrifugal filter tubes with a molecular weight cut off of 30 kd and centrifuged at 5,000 Â g at 20 minutes. The solute (200 KL) retained in the filter unit was transferred to cultured neurons. Such molecular sieving of CM using an ultrafiltration technique almost completely (998%) eliminated AA peptide in the CM as determined by immunoblots of AA (1:2000) (data not shown). Astrocyte CM was then added to cultured neurons, and levels of synaptophysin and PSD95 were determined by immunoblotting using antibodies to synaptophysin (1:2000) and PSD95 (1:1500).
Immunocytochemistry
Cultured neurons were fixed in ice-cold methanol for 10 minutes and washed 3 times with cold PBS. Cultures were blocked in 5% bovine serum albumin (dissolved in PBS containing 0.1% Triton X-100 [PBS-T]) for 30 minutes and then incubated with a primary antibody to synaptophysin (1:250, prepared in 2.5% bovine serum albumin) overnight at 4-C. Cultures were washed with PBS-T and then incubated with AlexaFluor 488 fluorescent horseradish peroxidaseY conjugated secondary antibodies (1:400) for 1 hour. Cultures were washed 5 times with PBS-T and incubated in 0.001% 4 ¶,6-diamidino-2-phenylindole (nuclear stain) solution for 15 minutes. Culture plates were mounted with coverslips and examined with a laser scanning confocal microscope (Nikon). Random collection of images was achieved by systematically capturing each image in a blinded manner and by moving the microscope platform by approximately 5 mm 2 area in 4 different directions.
Fluorescent intensities in both control and experimental groups were analyzed using the QCapture Pro Image Acquisition and Analysis software (Surrey, BC, Canada). Briefly, 6 to 8 random images were selected in each group; in each image, at least 7 to 10 regions of interest (ROI) were randomly selected; and in each ROI, the total number of pixels were quantified on a gray scale (0Y255 counts). The mean pixel value in each ROI was obtained, and the total pixel intensities from all of the image fields were averaged and expressed as mean T SEM of the total number of mean pixel values in each experiment.
Cell Viability Assay
Neuronal viability after the addition of CM from AAtreated astrocytes was determined by the MTT assay using a commercially available kit (R&D Systems, Inc., Minneapolis, MN). Briefly, 24 hours after the addition of CM from AAtreated astrocytes to neuronal cultures, 200 KL of the MTT reagent was added to cultures and incubated for 4 hours at 37-C. After visualization of precipitates, 500 KL of 10% sodium dodecyl sulfate was added to the cultures and incubated for an additional 24 hours at 37-C; absorbance of control and experimental samples were then measured at 570 nm. The absorbance of the control sample was set at 100%, and cell viability was expressed as percent change from control.
Statistical Analysis
Data are expressed as mean T SEM and analyzed by analysis of variance followed by the Newman-Keuls multiple range test. A value of p G 0.05 was considered statistically significant.
RESULTS
Effect of AA on TSP-1 Protein Release From Cultured Astrocytes
In preliminary studies, we first examined levels of TSP-1 in the culture media from untreated (control) astrocytes at different time points (30 minutesY12 hours) and found that TSP-1 protein levels did not change at any time point (data not shown). Accordingly, in subsequent studies, we used culture media from control astrocytes at time points that corresponded to the AA treatment times. Treatment of cultures with AA (4 Kmol/L) showed a time-dependent reduction in the extracellular concentration of TSP-1 protein. At 3 hours, there was no change in the TSP-1 content in astrocyte media as compared with media from untreated astrocytes (controls), whereas at 6 hours after treatment, a 50% reduction was identified, which persisted for up to 24 hours (Fig. 1A, B) . To confirm that the TSP band that was identified in the experimental samples was indeed TSP-1, a separate immunoblot was performed using protein samples of CM from untreated and AA-treated astrocytes, along with purified human TSP-1. We found that protein bands from control and AA-treated astrocyte CM at 130 kd colocalized with human TSP-1 (Fig. 1A) .
Effect of AA on Cellular Levels of TSP-1 in Cultured Astrocytes
To examine whether a reduction in TSP-1 release into the astrocyte media is caused by a reduced cellular content of TSP-1 or to a defective release, intracellular TSP-1 protein levels were determined in cultured astrocytes after treatment with AA. This treatment caused a marked increased in TSP-1 content in cultured astrocytes. At 3 and 6 hours, there was approximately 300% (p G 0.001) increase in TSP-1 protein level as compared with that of untreated astrocytes (controls). At 12 and 24 hours, there was a decline, but TSP-1 levels were still higher as compared with those in controls (171% at 12 hours and 102% at 24 hours, p G 0.01) ( Fig. 2A, B) .
Effect of AA on TSP-1 mRNA Content in Cultured Astrocytes
We next examined TSP-1 mRNA levels at different time points (30 minutesY24 hours) to establish whether the increased intracellular TSP-1 found in cultured astrocytes after AA treatment could be caused by its increased neosynthesis. We found no significant changes in TSP-1 mRNA level at 30 minutes, 1 hour, 3 hours, and 6 hours after AA treatment, although at 12 and 24 hours, a nonsignificant rise (0.51-fold) in mRNA was detected (Fig. 3) . The findings of decreased TSP-1 release, together with its elevated intracellular level, suggest that the reduced extracellular TSP-1 content is indeed a consequence of impaired cellular release.
Effect of Antioxidants on TSP-1 Protein Content and Release in AA-Treated Cultured Astrocytes
Amyloid-A treatment of cultured astrocytes was previously shown to induce OS (10, 13, 24) mediated by the activation of NADPH oxidase (NOX) and associated increased levels of superoxide radicals (15) . Therefore, we examined whether OS contributed to the AA-mediated decrease in TSP-1 release from cultured astrocytes. Pretreatment of cultured astrocytes (10 minutes) with tempol (10 Kmol/L), a scavenger of superoxide, significantly (71%, p G 0.01) reduced AAmediated (6 hours) retention of TSP-1 in cultured astrocytes, whereas apocynin (200 Kmol/L), an inhibitor of NOX, completely blocked its retention (Fig. 4) . Treatment of cultured astrocytes with tempol and apocynin also led to a significant increase (71.2% and 69.5%, respectively, p G 0.01) in the release of TSP-1 into the media, which corresponded well with its reduction in cultured astrocytes (Fig. 5) . Treatment of cultured astrocytes with either tempol or apocynin, in the absence of AA, had no effect on cellular levels of TSP-1 or on its release (Figs. 4, 5) .
Effect of CM From AA-Treated Cultured Astrocytes on Synaptophysin Expression in Cultured Neurons
Astrocytes were treated with AA (4 Kmol/L) for different periods (6Y24 hours). To eliminate any residual AA in the culture media, the CM from control and AA-treated astrocytes were passed through Amicon centrifugal filters having a molecular weight cutoff 30 kd. The CM retained in the filter units was then added to cultured neurons, and 24 hours later, synaptophysin protein expression was determined by immunoblots and immunocytochemistry.
Addition of CM from AA-treated astrocytes (containing reduced amounts TSP-1 protein) to neurons resulted in a significant reduction in neuronal synaptophysin levels as a function of time (6Y24 hours). Immunoblot analysis showed a 33% (p G 0.05) reduction of synaptophysin at 6 hours, which was further reduced (48%Y60%, p G 0.01) at 12 and 24 hours (Fig. 6 ). Immunofluorescence analysis of cultured neurons exposed to CM from AA-treated astrocytes also showed a comparable reduction in synaptophysin protein immunoreactivity, particularly in neuronal processes (Fig. 7) . Quantification of synaptophysin immunofluorescence in neuronal cultures exposed to CM from astrocytes treated with AA showed a 50% reduction (p G 0.05) at 6 hours, which was further reduced (60%, p G 0.05) at 12 hours and 24 hours (Fig. 8) . Such reduction was not caused by neuronal loss as we found approximately equal number of cells in neuronal cultures exposed to control and AA-treated CM from astrocytes, as determined by counterstaining with the nuclear marker 4 ¶,6-diamidino-2-phenylindole (Fig. 7) . Phase-contrast images identical with immunofluorescence images also indicated that the neurons were intact (Fig. 7) . These data suggest that reduced TSP-1 protein content in the CM from AA-treated astrocytes is responsible for the decreased expression of neuronal synaptophysin. We also assessed the viability of neurons in cultures exposed to CM from AA-treated astrocytes using the MTT assay, which determines mitochondrial function as a measure of cell viability. Using this assay, we found that addition of CM from AA-treated astrocytes to neuronal cultures did not compromise cell viability (control CM, 100% T 6%; CM from astrocytes treated with AA, 93% T 4%).
To establish that the reduction in astrocytic TSP-1 was indeed responsible for the loss of neuronal synaptophysin, cultured astrocytes were treated with a mouse monoclonal antibody to TSP-1 (3 Kg, which shows cross reactivity with rat TSP-1) or with normal mouse IgG (5 Kg, control to antiYTSP-1 IgG) for 6 hours. After such treatments, the CM were added to cultured neurons, and synaptophysin expression was determined by immunoblots 12 hours later. The addition of CM from astrocytes treated with the TSP-1 antibody to cultured neurons resulted in a 54% (p G 0.01) reduction in synaptophysin expression (Fig. 9) , whereas CM from astrocytes treated with normal mouse IgG had no effect on synaptophysin expression (Fig. 9) . These findings support the view that astrocytic TSP-1 reduction after AA treatment is involved in the decrease in synaptophysin expression observed in neurons.
To confirm that astrocytic TSP-1 reduction indeed contributes to the loss of neuronal synaptophysin, CM from AA-treated astrocytes (6 hours) was supplemented with recombinant human TSP-1 ([rTSP-1] 500 ng), and this mixture was then added to cultured neurons for 24 hours. This treatment completely prevented the loss of synaptophysin (Fig. 10) . These data add credence to the view that a reduction in astrocytic TSP-1 caused by AA treatment is responsible for the loss of neuronal synaptophysin.
Effect of AA Exposure to Neurons on Synaptophysin Expression
To examine whether direct treatment of cultured neurons with AA reduces synaptophysin expression, neurons were exposed to AA (4 Kmol/L, the same concentration that was used in the treatment of astrocytes) and at different time points (6Y24 hours); synaptophysin expression was determined by immunoblots. Amyloid-A treatment of neurons had no effect on synaptophysin content (Fig. 11) .
Effect of CM From AA-Treated Cultured Astrocytes on PSD95 Expression in Cultured Neurons
In addition to synaptophysin expression, we also examined the effects of CM from AA-treated cultured astrocytes on the postsynaptic protein PSD95. We followed an identical procedure to that used for neuronal synaptophysin expression and found that the addition of CM from AAtreated astrocytes to cultured neurons showed a 55% reduction in neuronal PSD95 at 6 hours, which persisted for up to 24 hours (Fig. 12) .
DISCUSSION
This study demonstrates that treatment of cultured astrocytes with AA results in a significant reduction in the release of TSP-1, along with an increase in intracellular levels of this protein. Messenger RNA levels of TSP-1 after treatment with AA were not changed, suggesting that the increase in intracellular retention of TSP-1 was not caused by neosynthesis but rather to an impairment of its release. The antioxidant tempol and the NOX inhibitor apocynin significantly attenuated the AA-mediated reduction in TSP-1 release and diminished the intracellular retention of TSP-1, indicating a role for OS in the impairment of astrocytic TSP-1 release by AA. Furthermore, addition of CM from astrocytes treated with AA to cultured neurons resulted in a significant reduction in synaptophysin and PSD95 protein levels, suggesting that an astrocytic reduction in TSP-1 release by AA contributed to the loss of presynaptic and postsynaptic proteins. Synaptophysin expression was reduced in neurons exposed to CM from cultured astrocytes to which anti-TSP antibody was added, whereas CM from astrocytes exposed to normal IgG had no effect. Values in each group are mean T SEM of 2 individual culture plates taken from 2 separate seeding batches (n = 4). * versus control (p G 0.01). C, CM from untreated (control) astrocytes; Normal IgG, CM from astrocytes treated with normal IgG; AntiYTSP-1 IgG, CM from astrocytes treated with antibody to TSP-1. The mechanism(s) by which AA results in a reduction in astrocytic TSP-1 secretion is (are) not known, but AA has been shown to induce OS, possibly by the excessive production of superoxide mediated by NOX (2, 25, 26) . Likewise, an increase in heme oxygenase 1, a marker of OS, was found in cultured astrocytes exposed to AA (27) . In this study, we found that tempol, a scavenger of superoxide, and apocynin, an inhibitor of NOX, both significantly inhibited the AA-mediated reduction in TSP-1 release and the concomitant elevation of its cellular level. These data suggest that OS indeed contributes to the intracellular retention of TSP-1 and corresponding reduction of its release.
In support of the view that AA-mediated OS contributes to a reduction in TSP-1 release, a recent study by Chen et al (28) found that OS induced by the respiratory chain inhibitor cobalt chloride (CoCl 2 ) reduced mRNA and protein levels of TSP-1 in cultured astrocytes and that the antioxidant N-acetylcysteine significantly inhibited the reduction in TSP-1 mRNA and protein expression. However, our results are at variance with that of Chen et al (28) as we found that antioxidants (tempol and apocynin) accelerated the cellular release of TSP-1 and reduced its retention in astrocytes. The reason for these discrepancies is not known, but it is possible that other effects of CoCl 2 may have contributed to the different outcomes.
A seminal study by Allaman et al (14) recently documented that the addition of CM from AA-treated astrocytes to neurons resulted in a loss of synaptophysin. The factors and mechanism(s) involved in such loss were not established. Our studies have established that a reduction in TSP-1 release is likely a major event responsible for the reduction in neuronal synaptophysin. Furthermore, addition of CM from AA-treated astrocytes to neurons also resulted in a similar reduction in PSD95, a postsynaptic protein. Immunofluorescence analysis showed that the reduction in synaptophysin was more prominent in neuronal processes and was not caused by neuronal loss (Fig. 8) . The possibility that residual AA peptide (4.5 kd) in the astrocyte CM might have contributed to loss of synaptophysin can be excluded because the CM was passed through a centrifugal filter with a 30-kd molecular weight cutoff, thereby eliminating molecules less than 30 kd. This procedure also excludes the possibility that other small-molecular-weight particles, such as arachidonic acid, prostaglandins, and cytokines, among others (29) , may have contributed to neuronal synaptophysin loss.
We also examined the direct effects of AA on synaptophysin expression in cultured neurons and found that a concentration of AA (4 Kmol/L), similar to that used in the treatment of astrocytes, had no effect on synaptophysin protein levels. These data are consistent with a report by Kimura et al (30) who also observed that AA (5 Kmol/L) treatment (48 hours) to cortical neurons had no effect on synaptophysin levels. In contrast to these observations, some investigators have reported a reduction in synaptophysin expression by a direct treatment of cultured neurons with AA (1Y15 Kmol/L) (31Y34). These studies used cultured hippocampal neurons that perhaps may display increased vulnerability to AA-mediated toxicity as compared with that in cortical neurons. It should also be noted that, in cortical neurons, only higher concentrations (10Y25 Kmol/L) and longer exposure (24Y72 hours) of AA resulted in a reduction in synaptophysin levels (35, 36) .
In recent years, there has been a surge of interest in the role of astrocytes in the pathogenesis of AD (8) . Studies using cultured astrocytes have shown that these cells possess mechanisms that take up and degrade AA peptides (37) . Exposure of cultured astrocytes to AA were shown not only to trigger reactive astrocytosis but also to induce metabolic alterations, including increases in intracellular Ca 2+ release (9), induction of oxidative and nitrosative stress (10) , reduction in glutamate uptake capacity (11Y13), decreased glucose metabolism (14) , and induction of the mitochondrial permeability transition (15) ; the latter may lead to mitochondrial dysfunction, bioenergetic failure, and promoting OS (8, 16) .
Recent studies have documented that astrocytes regulate the development, maturation, and integrity of synapses (17, 18, 38Y40) . Such activity was shown to be mediated by matricellular proteins referred to as TSP, particularly TSP-1, which, in brain, is predominantly secreted by astrocytes (17, 38Y40) . Accordingly, addition of CM from astrocytes cultured from TSP-1Yknockout mice, as well as from cultured astrocytes in which TSP-1 gene was silenced (by siRNA), showed a reduction in neuronal synaptophysin levels and shortening of neuronal spine morphology (41, 42) . Our results showing a reduction in synaptophysin and PSD95 expression in neurons by the addition of astrocytic CM containing monoclonal antibody to TSP-1 are in agreement with the above reports. The finding that the addition of CM from AA-treated astrocytes containing rTSP-1 to neurons completely prevented the loss of neuronal synaptophysin caused by CM from AAtreated astrocytes strongly supports the view that depletion of astrocytic TSP-1 by AA represents a crucial factor in the loss of neuronal synaptophysin.
The present study also showed that treatment of cultured astrocytes with AA significantly inhibited the release of TSP-1 from astrocytes. These data are consistent with a recent report showing reduced extracellular levels of TSP-1 in human astrocyte cultures from fetuses with Down syndrome (42), a disorder with a strong predilection for the development of AD (43Y45).
It is reasonable to suggest that defects in exocytotic/ secretory pathways that transport TSP-1 into the extracellular space may contribute to its decreased release. Whereas the means by which TSP-1 is transported out of the cells are not completely understood, studies have shown that >-actinin, a cytoskeletal protein that binds to TSP-1, may act as carrier of TSP-1 to the plasma membrane where it is presumably exocytosed (46, 47) . It is notable that >-actinin protein expression was reduced in brains of a transgenic mouse model of AD (48) . Whether a comparable reduction in >-actinin may have contributed to cellular retention of TSP-1 in our cultured astrocytes treated with AA remains to be determined.
In summary, treatment of cultured astrocytes with AA increased the cellular retention of TSP-1 and reduced its release into astrocyte culture media. The antioxidant tempol and the NOX inhibitor apocynin significantly attenuated these events, suggesting the involvement of OS in the reduction in TSP-1 release and its increased cellular retention. Conditioned media from AA-treated astrocytes when added to neurons resulted in a significant reduction in the expression of the presynaptic and postsynaptic proteins synaptophysin and PSD95. The direct addition of AA to cultured neurons had no effect on synaptophysin expression. Together, these data suggest that a reduction in TSP-1 release from AA-treated astrocytes, likely caused by OS, ultimately leads to the loss of synaptophysin and PSD95 in neurons and associated synaptic dysfunction. Strategies to enhance the release of TSP-1 from astrocytes may have therapeutic efficacy in AD.
